Recently, a secondary analysis of a randomized clinical trial of immunomodulatory therapy in COVID-19 provided evidence that decreases in IL-6 mediated benefit from treatment and that baseline biomarker levels alone could not similarly predict treatment response [32]. This evidence concerns the gene IL6 and COVID-19.